Hiltrud M.
- Country
- Germany
- Department
- Klinik für Kinder- und Jugendmedizin II Abteilung für Neuropädiatrie und Sozialpädiatrie
Research Overview
- Long-term Safety Evaluation of Fenfluramine Hydrochloride as Adjunctive Therapy in Patients with Myoclonic Astatic Epilepsy (Doose Syndrome)
- Evaluation of Cenobamate as Adjunctive Therapy in Patients Aged 12 and Older with Primary Generalized Tonic-Clonic Seizures: A Randomized, Double-Blind, Placebo-Controlled Study
- Long-term Safety Evaluation of Cenobamate as Adjunctive Therapy in Patients with Primary Generalized Tonic-Clonic Seizures: A Multicenter Open-label Extension Study
Data & Insights
Has run more than one trial at 49 of 68 partner sites.
Specializations
Epilepsy Disorders
This investigator specializes in treating various forms of complex epilepsy conditions, with particular focus on Myoclonic Astatic Epilepsy (Doose Syndrome) and Primary Generalized Tonic-Clonic Seizures. Their research extends to innovative therapeutic approaches for managing these challenging neurological conditions.
- Myoclonic Astatic Epilepsy management
- Tonic-Clonic Seizure treatment
- Long-term seizure control strategies
The investigator's work encompasses comprehensive evaluation of seizure patterns and treatment responses in various epilepsy manifestations.
Rare Neurological Conditions
The investigator has developed expertise in treating rare neurological disorders, particularly Dravet Syndrome and CDKL5 Deficiency Disorder. Their research focuses on developing therapeutic interventions for these challenging genetic conditions.
- Dravet Syndrome therapy
- CDKL5 Deficiency management
- Genetic epilepsy treatments
Their work involves evaluating novel therapeutic approaches for rare neurological disorders that typically manifest in early childhood.
Treatment Innovation
The investigator explores innovative therapeutic applications, focusing on adjunctive therapy approaches and long-term safety monitoring in epilepsy treatment. Their research examines the potential of various therapeutic compounds in managing complex neurological conditions.
- Novel therapeutic compounds
- Add-on therapy evaluation
- Safety monitoring protocols
Their work emphasizes the development and assessment of new treatment options for patients with drug-resistant epilepsy forms.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.